The Consultants will comply with all applicable securities laws, including the policies of the CSE in providing their services to the Company.
Toronto, Ontario--(Newsfile Corp. - February 1, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (“Mindset” or the “Company”), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce it has engaged the services of Black Vulcan Resources, LLC (“Black Vulcan”) and Angstrom Capital Ltd. (“Angstrom” and together with Black Vulcan, the “Consultants”) to assist the Company with business strategy and corporate development.
As consideration for their services, each of Black Vulcan and Angstrom will be paid: (i) an aggregate of 1,000,000 common shares in the capital of the Company, issuable in tranches; and (ii) a cash payment in the aggregate of $150,000, paid over a ten-month term in accordance with the respective consulting agreement entered into by the Company with each of Black Vulcan and Angstrom, all subject to the approval of the Canadian Securities Exchange (“CSE”). The Consultants will comply with all applicable securities laws, including the policies of the CSE in providing their services to the Company.
For further information, on Mindset, along with a video overview of the Company, please visit our website at: www.mindsetpharma.com
FOR MORE INFORMATION, PLEASE CONTACT:
James Lanthier
CEO
jlanthier@mindsetpharma.com
Jason Atkinson
VP, Corporate Development
jatkinson@mindsetpharma.com
About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psilocybin-inspired medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin along with its own proprietary compounds. www.mindsetpharma.com
Forward-Looking Information
This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change, unless required by law. The reader is cautioned not to place undue reliance on forward-looking information.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/73385
